Treatment features of pelvic inflammatory diseases in women with polycystic ovary syndrome
Keywords:polycystic ovarian syndrome, pelvic inflammatory diseases
Polycystic ovary syndrome (PCOS) is a common disease with frequency of 6 to 20% depending on the criteria used. Combined PCOS with pelvic inflammatory diseases (PID) lead to multicomponent damage of the reproductive system.
The aim of the study was the development of pathogenetic therapeutic algorithm for patients with PCOS on the background of PID-based study of the relations between the functioning of the pituitary-ovarian system and the flow characteristics of the inflammatory process. Medical complex consisted of antibiotic therapy, antifungal drugs, as well as glutoxim, normocycle, noofen, api-norm, polygynax.
49 patients with PCOS against the backdrop of PID (the main group) were treated according to the developed scheme. The comparison group consisted of 31 women who underwent only standard antibacterial and antifungal therapy.
After treatment in the main group was more marked decrease in the frequency of complaints of aching pain in the lower abdomen. Regular menstrual cycle is established in 59.2%of women of the main group, which was significantly higher than in comparison group – 22.6% of the patients. Combined therapy helped restore steroid production by ovarian, which manifested in increase the estrogen and progesterone synthesis, and was accompanied by a decrease in androgen level. Bacterioscopic study after treatment in both groups showed a decrease in the proportion of III and IV degrees of vaginal cleanliness and increase of II degree. In the main group after treatment the proportion of I and II degrees almost 2 times was higher than in the comparison group.
Studies have shown that the use of the developed treatment helps to eliminate the symptoms of inflammation, reduction of contamination of the genital tract by pathogenic and opportunistic microflora, improve vascularity and ovarian function which was manifested in ovulatory cycles increasing from 14.3% to 73.5% with normalization of hormonal homeostasis.
- Ehrmann, D. “Polycystic ovary syndrome.” New England Journal of Medicine 352 (2005).
- Kaluginа, N.V., Yefymenko, O.A. “Experience in the treatment of polycystic ovary syndrome.” Reproductive endocrinology 2.4 (2012): 74–78.
- Katsikis, I., Karkanaki, A., Misichronis, G., et al. “Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.” Eur J Obstet Gynecol Reprod Biol 156 (2011):181–5.
- Balen, A.H., Conway, G.S., Kaltsas, G. “Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.” Hum Reprod 10 (1995):2107–11.
- Podolskyi, V.V., Lysyana, T.O., Ponomariova, I.G. “Microbiota status of urogenital organs in women with reproductive health disorders and vegetative homeostasis changes.” Women’s Health 2 (2015): 142–150.
- The Order of the MOH of Ukraine from 10.05.2007 №234 “Organization of the prevention of nosocomial infections in obstetric hospitals”.
- Clinical protocol for obstetric and gynecological care “Sexually transmitted infections”. The Order of the MOH of Ukraine from 15.12.2003 №582.
How to Cite
Copyright (c) 2016 Н. В. Косей, Т. О. Лісяна, Г. В. Ветох
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.